1. Home
  2. MARPS vs PPBT Comparison

MARPS vs PPBT Comparison

Compare MARPS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marine Petroleum Trust Units of Beneficial Interest

MARPS

Marine Petroleum Trust Units of Beneficial Interest

N/A

Current Price

$4.38

Market Cap

9.1M

Sector

Energy

ML Signal

N/A

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.83

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARPS
PPBT
Founded
1956
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MARPS
PPBT
Price
$4.38
$0.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.7K
290.8K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
7.84%
N/A
EPS Growth
N/A
N/A
EPS
0.31
N/A
Revenue
$965,040.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$0.53
52 Week High
$7.90
$5.20

Technical Indicators

Market Signals
Indicator
MARPS
PPBT
Relative Strength Index (RSI) 52.53 53.10
Support Level $4.19 $0.78
Resistance Level $4.33 $0.89
Average True Range (ATR) 0.11 0.07
MACD 0.03 0.01
Stochastic Oscillator 47.20 68.67

Price Performance

Historical Comparison
MARPS
PPBT

About MARPS Marine Petroleum Trust Units of Beneficial Interest

Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: